PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
29361614-7	2017	The addition of vascular endothelial growth factor(VEGF) inhibitor bevacizumab to the standard CDDP/PEM provides a 2.7-month survival benefit.	3-(2-phenylethyl)-4-methylsydnone	100-103	vascular endothelial growth factor A	Homo sapiens	16-50
33464839-7	2020	In lung cancer-bearing mice using urethane as a chemical carcinogen, the inhalable LF/CS-coated PEM-RES-LCNP nanocomposites showed superior antitumor activity as revealed by a considerable decrease of the average lung weight, reduced number and diameter of cancerous lung foci, decreased expression of VEGF-1, and increased expression of active caspase-3 as well as reduced Ki-67 expression compared to the spray-dried free PEM/RES powder mixture and positive control.	3-(2-phenylethyl)-4-methylsydnone	96-99	caspase 3	Mus musculus	345-354
33464839-7	2020	In lung cancer-bearing mice using urethane as a chemical carcinogen, the inhalable LF/CS-coated PEM-RES-LCNP nanocomposites showed superior antitumor activity as revealed by a considerable decrease of the average lung weight, reduced number and diameter of cancerous lung foci, decreased expression of VEGF-1, and increased expression of active caspase-3 as well as reduced Ki-67 expression compared to the spray-dried free PEM/RES powder mixture and positive control.	3-(2-phenylethyl)-4-methylsydnone	96-99	antigen identified by monoclonal antibody Ki 67	Mus musculus	374-379
31791326-8	2019	RESULTS: PTK2 was hyperphosphorylated in PC-9/PEM.	3-(2-phenylethyl)-4-methylsydnone	46-49	PTK2 protein tyrosine kinase 2	Mus musculus	9-13
31791326-10	2019	Combination of PTK2 inhibitor and EGFR-TKI inhibited Akt and induced apoptosis in PC-9/PEM.	3-(2-phenylethyl)-4-methylsydnone	87-90	PTK2 protein tyrosine kinase 2	Mus musculus	15-19
31791326-10	2019	Combination of PTK2 inhibitor and EGFR-TKI inhibited Akt and induced apoptosis in PC-9/PEM.	3-(2-phenylethyl)-4-methylsydnone	87-90	epidermal growth factor receptor	Mus musculus	34-38
31414228-11	2019	Immunofluorescence and western blotting studies showed that PEM/Rg3 inhibited the expressions of interleukin 1 (IL-1), interleukin 6 (IL-6), and reactive oxygen species modulator-1 (ROMO1).	3-(2-phenylethyl)-4-methylsydnone	60-63	interleukin 6	Mus musculus	119-132
31414228-11	2019	Immunofluorescence and western blotting studies showed that PEM/Rg3 inhibited the expressions of interleukin 1 (IL-1), interleukin 6 (IL-6), and reactive oxygen species modulator-1 (ROMO1).	3-(2-phenylethyl)-4-methylsydnone	60-63	interleukin 6	Mus musculus	134-138
31414228-11	2019	Immunofluorescence and western blotting studies showed that PEM/Rg3 inhibited the expressions of interleukin 1 (IL-1), interleukin 6 (IL-6), and reactive oxygen species modulator-1 (ROMO1).	3-(2-phenylethyl)-4-methylsydnone	60-63	reactive oxygen species modulator 1	Mus musculus	182-187
29361614-7	2017	The addition of vascular endothelial growth factor(VEGF) inhibitor bevacizumab to the standard CDDP/PEM provides a 2.7-month survival benefit.	3-(2-phenylethyl)-4-methylsydnone	100-103	vascular endothelial growth factor A	Homo sapiens	51-55
19786904-6	2009	RESULTS: In all patients with advanced NSCLC regardless of histologic subtype, using Cis/Pem as first-line chemotherapy led to an incremental cost per life-year gained (LYG) of $104,577 for Cis/Pem to Cis/Gem and $231,291 for Cis/Pem to Carb/Pac.	3-(2-phenylethyl)-4-methylsydnone	89-92	syntaxin 8	Homo sapiens	237-241
22005471-9	2011	Compared with the Doc/Carb group, fewer patients in the Pem/Carb group experienced grade 3/4 drug-related, treatment-emergent neutropenia, leukopenia, or febrile neutropenia, and more patients experienced anemia and thrombocytopenia.	3-(2-phenylethyl)-4-methylsydnone	56-59	syntaxin 8	Homo sapiens	22-26
19786904-8	2009	The incremental cost per LYG for Carb/Pac/Bev to Cis/Pem was more than $300,000.	3-(2-phenylethyl)-4-methylsydnone	53-56	syntaxin 8	Homo sapiens	33-37
12100521-3	2002	Staining scores for Bcl-2 in the dEM, endometrial hyperplasia (EMH) and endometrioid cancer (ECA) groups were higher than in the pEM group (P = 0.004; P = 0.036 and P = 0.020, respectively).	3-(2-phenylethyl)-4-methylsydnone	129-132	BCL2 apoptosis regulator	Homo sapiens	20-25
6435619-2	1984	The acquisition of tumoricidal properties by PEM challenged with macrophage activating factor (MAF) plus lipopolysaccharide (LPS) was inhibited in a dose-dependent fashion by CsA.	3-(2-phenylethyl)-4-methylsydnone	45-48	MAF bZIP transcription factor	Homo sapiens	95-98
2344374-1	1990	3-[2-(2,4,6-Trimethylphenyl)thioethyl]-4-methylsydnone (TTMS) and 3-(2-phenylethyl)-4-methylsydnone (PEMS) cause mechanism-based inactivation of rat hepatic microsomal cytochrome P-450 and the formation of N-alkylprotoporphyrins in rat liver.	3-(2-phenylethyl)-4-methylsydnone	66-99	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	168-184
35051357-2	2022	Using lung tumor models, where pemetrexed and cisplatin (PEM/CDDP) chemotherapy remains unable to synergize with immune checkpoint inhibitors (ICIs), we linked the failure of this treatment with its inability to induce CXCL10 expression and CD8+ T cell recruitment.	3-(2-phenylethyl)-4-methylsydnone	57-60	C-X-C motif chemokine ligand 10	Homo sapiens	219-225
35051357-2	2022	Using lung tumor models, where pemetrexed and cisplatin (PEM/CDDP) chemotherapy remains unable to synergize with immune checkpoint inhibitors (ICIs), we linked the failure of this treatment with its inability to induce CXCL10 expression and CD8+ T cell recruitment.	3-(2-phenylethyl)-4-methylsydnone	57-60	CD8a molecule	Homo sapiens	241-244
35051357-3	2022	Using drug screening, we showed that combining a MEK inhibitor (MEKi) with PEM/CDDP triggers CXCL10 secretion by cancer cells and CD8+ T cell recruitment, sensitizing it to ICIs.	3-(2-phenylethyl)-4-methylsydnone	75-78	mitogen-activated protein kinase kinase 7	Homo sapiens	49-52
35051357-3	2022	Using drug screening, we showed that combining a MEK inhibitor (MEKi) with PEM/CDDP triggers CXCL10 secretion by cancer cells and CD8+ T cell recruitment, sensitizing it to ICIs.	3-(2-phenylethyl)-4-methylsydnone	75-78	C-X-C motif chemokine ligand 10	Homo sapiens	93-99
35051357-3	2022	Using drug screening, we showed that combining a MEK inhibitor (MEKi) with PEM/CDDP triggers CXCL10 secretion by cancer cells and CD8+ T cell recruitment, sensitizing it to ICIs.	3-(2-phenylethyl)-4-methylsydnone	75-78	CD8a molecule	Homo sapiens	130-133
35051357-4	2022	PEM/CDDP plus a MEKi promotes optineurin (OPTN)-dependent mitophagy, resulting in CXCL10 production in a mitochondrial DNA- and TLR9-dependent manner.	3-(2-phenylethyl)-4-methylsydnone	0-3	optineurin	Homo sapiens	30-40
35051357-4	2022	PEM/CDDP plus a MEKi promotes optineurin (OPTN)-dependent mitophagy, resulting in CXCL10 production in a mitochondrial DNA- and TLR9-dependent manner.	3-(2-phenylethyl)-4-methylsydnone	0-3	optineurin	Homo sapiens	42-46
35051357-4	2022	PEM/CDDP plus a MEKi promotes optineurin (OPTN)-dependent mitophagy, resulting in CXCL10 production in a mitochondrial DNA- and TLR9-dependent manner.	3-(2-phenylethyl)-4-methylsydnone	0-3	C-X-C motif chemokine ligand 10	Homo sapiens	82-88
35051357-4	2022	PEM/CDDP plus a MEKi promotes optineurin (OPTN)-dependent mitophagy, resulting in CXCL10 production in a mitochondrial DNA- and TLR9-dependent manner.	3-(2-phenylethyl)-4-methylsydnone	0-3	toll like receptor 9	Homo sapiens	128-132
35051357-5	2022	TLR9 or autophagy/mitophagy inhibition abolishes the anti-tumor efficacy of PEM/CDDP plus MEKi/anti-PD-L1 therapy.	3-(2-phenylethyl)-4-methylsydnone	76-79	toll like receptor 9	Homo sapiens	0-4
2844240-2	1988	Incubation of 3-(2-phenylethyl)-4-methylsydnone (PMS) with liver microsomes from phenobarbital-pretreated rats or with reconstituted cytochrome P-450b results in loss of the enzyme chromophore.	3-(2-phenylethyl)-4-methylsydnone	14-47	cytochrome P450, family 2, subfamily b, polypeptide 1	Rattus norvegicus	133-150
2844240-2	1988	Incubation of 3-(2-phenylethyl)-4-methylsydnone (PMS) with liver microsomes from phenobarbital-pretreated rats or with reconstituted cytochrome P-450b results in loss of the enzyme chromophore.	3-(2-phenylethyl)-4-methylsydnone	49-52	cytochrome P450, family 2, subfamily b, polypeptide 1	Rattus norvegicus	133-150
2844240-7	1988	No spectroscopically detectable intermediates precede chromophore loss in incubations of reconstituted cytochrome P-450b with PMS.	3-(2-phenylethyl)-4-methylsydnone	126-129	cytochrome P450, family 2, subfamily b, polypeptide 1	Rattus norvegicus	103-120
33839365-11	2021	Moreover, pem-chemo and nivo-ipi-chemo appear to be superior first-line immunotherapy combinations for advanced NSCLC patients with positive and negative PD-L1 expression, respectively.	3-(2-phenylethyl)-4-methylsydnone	10-13	CD274 molecule	Homo sapiens	154-159
33561074-7	2020	In the PD-L1 positive (>=1%) patient subgroup, Pem (10 mg/kg) ranked the highest in efficacy for OS, followed by Niv, Pem (2 mg/kg), Atz, and Doc.	3-(2-phenylethyl)-4-methylsydnone	47-50	CD274 molecule	Homo sapiens	7-12